Advances in Molecular OncologyAdvances in Molecular OncologyУспехи молекулярной онкологии2313-805X2413-3787Publishing House ABV Press84910.17650/2313-805X-2026-13-2-26-36REVIEW ARTICLESОБЗОРНЫЕ СТАТЬИReview ArticleThe immune microenvironment and promising strategies for neuroblastoma therapyИммунное микроокружение и перспективные стратегии терапии нейробластомыhttps://orcid.org/0009-0001-3534-2911KarpovGleb A.КарповГлеб Андреевич
Russian Federation
gleb13.karpov@gmail.comhttps://orcid.org/0000-0003-1308-8622DruyA. E.ДруйА. Е.
Russian Federation
gleb13.karpov@gmail.comN.I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава РоссииDmitry Rogachev National Medical Research Center Of Pediatric Hematology, Oncology and Immunology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава РоссииDr. Sergey Berezin Medical InstituteМеждународный институт биологических систем им. Сергея Березина19062026132263610022026Copyright ©; 2026, ABV-PressCopyright ©; 2026, АБВ-пресс2026ABV-PressАБВ-прессhttps://umo.abvpress.ru/jour/about/editorialPolicieshttps://umo.abvpress.ru/jour/article/view/849

Neuroblastoma is a malignant tumor found in children and characterized by exceptional heterogeneity and complex microenvironment which plays a key role in disease progression and response to therapy. The review summarizes the modern data on cell composition of neuroblastoma microenvironment and its effect on prognosis promoting formation of promising treatment strategies. Modulation of tumor microenvironment can become the key approach to development of effective targeted therapy and immunotherapy for various types of neuroblastoma.

Нейробластома – злокачественная опухоль детского возраста, характеризующаяся исключительной гетерогенностью и сложным микроокружением, которое играет определяющую роль в прогрессировании заболевания и ответе на терапию. В обзоре систематизированы современные данные о клеточном составе микроокружения нейробластомы и его влиянии на прогноз, способствующие формированию перспективных стратегий лечения. Модуляция микроокружения этой опухоли может быть ключевым направлением для разработки эффективной таргетной терапии и иммунотерапии при разных типах нейробластомы.

tumor microenvironmentimmunotherapyprognosisneuroblastomaопухолевое микроокружениеиммунотерапияпрогнознейробластомаCheung N.V., Dyer M.A. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer 2013;13(6):397–411. DOI: 10.1038/nrc3526Blavier L., Yang R., DeClerck Y.A. The tumor microenvironment in neuroblastoma: new players, new mechanisms of interaction and new perspectives Cancers (Basel) 2020;12(10):2912. DOI: 10.3390/cancers12102912Gunaydin G. CAFs interacting with TAMs in tumor microenvironment to enhance tumorigenesis and immune evasion. Front Oncol 2021;11:668349. DOI: 10.3389/fonc.2021.668349Sahai E., Astsaturov I., Cukierman E. et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer 2020;20(3):174–86. DOI: 10.1038/s41568-019-0238-1Hashimoto O., Yoshida M., Koma Y. et al. Collaboration of cancer-associated fibroblasts and tumour-associated macrophages for neuroblastoma development. J Pathol 2016;240(2):211–23. DOI: 10.1002/path.4769Mosser D.M., Edwards J P. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008;8(12):958–69. DOI: 10.1038/nri2448DeNardo D.G., Barreto J.B., Andreu P. et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009;16(2):91–102. DOI: 10.1016/j.ccr.2009.06.018Ganesan A.P., Johansson M., Ruffell B. et al. Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma. J Immunol 2013;191(4):2009–17. DOI: 10.4049/jimmunol.1301317Purwar R., Schlapbach C., Xiao S. et al. Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med 2012;18(8):1248–53. DOI: 10.1038/nm.2856Sun Y., Xu S. Tumor-associated CD204-positive macrophage is a prognostic marker in clinical stage I lung adenocarcinoma. Biomed Res Int 2018;2018:8459193. DOI: 10.1155/2018/8459193Asgharzadeh S., Salo J.A., Ji L. et al. Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. J Clin Oncol 2012;30(28):3525–32. DOI: 10.1200/jco.2011.40.9169Zhang P., Wu X., Basu M. et al. MYCN amplification is associated with repressed cellular immunity in neuroblastoma: an in silico immunological analysis of TARGET database. Front Immunol 2017;8:1473. DOI: 10.3389/fimmu.2017.01473Mina M., Boldrini R., Citti A. et al. Tumor-infiltrating T lymphocytes improve clinical outcome of therapy-resistant neuroblastoma. OncoImmunology 2015;4(9):e1019981. DOI: 10.1080/2162402x.2015.1019981Zhong X., Zhang Y., Wang L. et al. Cellular components in tumor microenvironment of neuroblastoma and the prognostic value. Peer J 2019;7:e8017. DOI: 10.7717/peerj.8017Morandi F., Pozzi S., Barco S. et al. CD4+CD25hiCD127− Treg and CD4+CD45R0+CD49b+LAG3+ Tr1 cells in bone marrow and peripheral blood samples from children with neuroblastoma. OncoImmunology 2016;5(12):e1249553. DOI: 10.1080/2162402x.2016.1249553Schaafsma E., Jiang C., Cheng C. B cell infiltration is highly associated with prognosis and an immune-infiltrated tumor microenvironment in neuroblastoma. J Cancer Metastasis Treat 2021;7(34):10.20517/2394-4722.2021.72. DOI: 10.20517/2394-4722.2021.72Mei S., Alchahin A.M., Embaie B.T. et al. Single-cell analyses of metastatic bone marrow in human neuroblastoma reveals microenvironmental remodeling and metastatic signature. JCI Insight 2024;9(6):e173337. DOI: 10.1172/jci.insight.173337Wei J.S., Kuznetsov I.B., Zhang S. et al. Clinically relevant cytotoxic immune cell signatures and clonal expansion of T-cell receptors in HIGH-RISK MYCN-not-amplified human neuroblastoma. Clin Cancer Res 2018;24(22):5673–84. DOI: 10.1158/1078-0432.ccr-18-0599Layer J.P., Kronmüller M.T., Quast T. et al. Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression. OncoImmunology 2017;6(6):e1320626. DOI: 10.1080/2162402x.2017.1320626Raffaghello L., Prigione I., Airoldi I. et al. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia 2004;6(5):558–68. DOI: 10.1593/neo.04316Wienke J., Visser L.L., Kholosy W.M. et al. Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy. Cancer Cell 2024;42(2):283–300.e8. DOI: 10.1016/j.ccell.2023.12.008Vanichapol T., Chutipongtanate S., Anurathapan U., Hongeng S. Immune escape mechanisms and future prospects for immunotherapy in neuroblastoma. Biomed Res Int 2018;2018:1812535. DOI: 10.1155/2018/1812535Castriconi R., Cantoni C., Della Chiesa M. et al. Transforming growth factor β1 inhibits expression of NKp30 and NKG2D receptors: Consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci USA 2003;100(7):4120–5. DOI: 10.1073/pnas.0730640100Park Y.P., Choi S., Kiesler P. et al. Complex regulation of human NKG2D-DAP10 cell surface expression: opposing roles of the γc cytokines and TGF-β1. Blood 2011;118(11):3019–27. DOI: 10.1182/blood-2011-04-346825Gao Y., Souza-Fonseca-Guimaraes F., Bald T. et al. Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells. Nat Immunol 2017;18(9):1004–15. DOI: 10.1038/ni.3800Zhen Z., Guo X., Liao R. et al. Involvement of IL-10 and TGF-β in HLA-E-mediated neuroblastoma migration and invasion. Oncotarget 2016;7(28):44340–9. DOI: 10.18632/oncotarget.10041Morandi F., Levreri I., Bocca P. et al. Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release. Cancer Res 2007;67(13):6433–41. DOI: 10.1158/0008-5472.can-06-4588Bergers G., Brekken R., McMahon G. et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2(10):737–44. DOI: 10.1038/35036374Itatani Y., Yamamoto T., Zhong C. et al. Suppressing neutrophil-dependent angiogenesis abrogates resistance to anti-VEGF antibody in a genetic model of colorectal cancer. Proc Natl Acad Sci USA 2020;117(35):21598–608. DOI: 10.1073/pnas.2008112117Condamine T., Dominguez G.A., Youn J.I. et al. Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. Sci Immunol 2016;1(2):aaf8943. DOI: 10.1126/sciimmunol.aaf8943Chao T., Furth E.E., Vonderheide R.H. CXCR2-dependent accumulation of tumor-associated neutrophils regulates T-cell immunity in pancreatic ductal adenocarcinoma. Cancer Immunol Res 2016;4(11):968–82. DOI: 10.1158/2326-6066.CIR-16-0188Morandi F., Barco S., Stigliani S. et al. Altered erythropoiesis and decreased number of erythrocytes in children with neuroblastoma. Oncotarget 2017;8(32):53194–209. DOI: 10.18632/oncotarget.18285Zeng L., Liu X.-Y., Chen K. et al. Phosphoserine phosphatase as an indicator for survival through potentially influencing the infiltration levels of immune cells in neuroblastoma. Front Cell Dev Bio 2022;10:873710. DOI: 10.3389/fcell.2022.873710Zhang Y., Zhang C., Ma Y. et al. Prediction to the prognosis of children with neuroblastoma by nomogram based on the first-diagnosed inflammatory markers. Pediatr Surg Int 2022;39(1):17. DOI: 10.1007/s00383-022-05302-zErbe A.K., Diccianni M.B., Mody R. et al. KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children’s Oncology Group. J Immunother Cancer 2023;11(2):e006530. DOI: 10.1136/jitc-2022-006530Fultang L., Gamble L.D., Gneo L. et al. Macrophage-derived IL1beta and TNFalpha regulate arginine metabolism in neuroblastoma. Cancer Res 2019;79(3):611–24. DOI: 10.1158/0008-5472.CAN-18-2139Stip M.C., Teeuwen L., Dierselhuis M.P. et al. Targeting the myeloid microenvironment in neuroblastoma. J Exp Clin Cancer Res 2023;42(1):337. DOI: 10.1186/s13046-023-02913-9Facciabene A., Motz G.T., Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res 2012;72(9):2162–71. DOI: 10.1158/0008-5472.can-11-3687Matthay K.K., Blaes F., Hero B. et al. Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004. Cancer Letters 2005;228(1–2):275–82. DOI: 10.1016/j.canlet.2005.01.051Ding X., Yang W., Ren Q. et al. Serum IgG-induced microglial activation enhances neuronal cytolysis via the NO/sGC/PKG pathway in children with opsoclonus-myoclonus syndrome and neuroblastoma. J Neuroinflammation 2020;17(1):190. DOI: 10.1186/s12974-020-01839-9Rudnick E., Khakoo Y., Antunes N.L. et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: Clinical outcome and antineuronal antibodies – a report from the Children’s cancer group study. Med Pediatr Oncol 2001;36(6):612–22. DOI: 10.1002/mpo.1138Gambini C., Conte M., Bernini G. et al. Neuroblastic tumors associated with opsoclonus-myoclonus syndrome: histological, immunohistochemical and molecular features of 15 Italian cases. Virch Arch 2003;442(6):555–62. DOI: 10.1007/s00428-002-0747-1Fukushima H., Inoue T., Takama Y. et al. Clinicopathological features of neuroblastic tumors with opsoclonus-myoclonus-ataxia syndrome: follicular structure predicts a better neurological outcome. Pathol Int 2017;67(10):503–9. DOI: 10.1111/pin.12591Fühlhuber V., Bick S., Kirsten A. et al. Elevated B-cell activating factor BAFF, but not APRIL, correlates with CSF cerebellar autoantibodies in pediatric opsoclonus-myoclonus syndrome. J Neuroimmunol 2009;210(1–2):87–91. DOI: 10.1016/j.jneuroim.2009.03.006Amini A., Lang B., Heaney D., Irani S.R. Multiple sequential antibody-associated syndromes with a recurrent mutated neuroblastoma. Neurology 2016;87(6):634–6. DOI: 10.1212/wnl.0000000000002945Olgun N., Arayici M.E., Kızmazoglu D., Cecen R.E. Assessment of chemo-immunotherapy regimens in patients with refractory or relapsed neuroblastoma: a systematic review with meta-analysis of critical oncological outcomes. J Clin Med 2025;14(3):934. DOI: 10.3390/jcm14030934Philippova J., Shevchenko J., Sennikov S. GD2-targeting therapy: a comparative analysis of approaches and promising directions. Front Immunol 2004;15:1371345. DOI: 10.3389/fimmu.2024.1371345Theruvath J., Menard M., Smith B.A.H. et al. Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication. Nat Med 2022;28(2):333–44. DOI: 10.1038/s41591-021-01625-xCoronado E., Yañez Y., Vidal E. et al. Intratumoral immunosuppression profiles in 11q-deleted neuroblastomas provide new potential therapeutic targets. Mol Oncol 2021;15(2):364–80. DOI: 10.1002/1878-0261.12868Liu X., Wills C.A., Chen L. et al. Tipifarnib inhibits the secretion of tumor-derived small extracellular vesicles and enhances the immunotherapeutic efficacy of dinutuximab in neuroblastoma. Cancer Res 2022;82(Suppl 12):4216. DOI: 10.1158/1538-7445.am2022-4216Liu X., Wills C.A., Chen L. et al. Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy. J Immunother Cancer 2022;10(4):e004399. DOI: 10.1136/jitc-2021-004399Rowshanrava B., Halliday N., Sansom D.M. CTLA-4: a moving target in immunotherapy. Blood 2017;131(1):58–67. DOI: 10.1182/blood-2017-06-741033Mao C., Poimenidou M., Craig B.T. Current knowledge and perspectives of immunotherapies for neuroblastoma. Cancers 2024;16(16):2865. DOI: 10.3390/cancers16162865Shirinbak S., Chan R.Y., Shahani S. et al. Combined immune checkpoint blockade increases CD8+CD28+PD-1+ effector T cells and provides a therapeutic strategy for patients with neuroblastoma. OncoImmunology 2021;10(1):1838140. DOI: 10.1080/2162402x.2020.1838140Majzner R.G., Simon J.S., Grosso J.F. et al. Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues. Cancer 2017;123(19):3807–15. DOI: 10.1002/cncr.30724Alborzinia H., Chen Z., Yildiz U. et al. LRP8-mediated selenocysteine uptake is a targetable vulnerability in MYCN-amplified neuroblastoma. EMBO Mol Med 2023;15(8):e18014. DOI: 10.15252/emmm.202318014Nomura M., Ueno A., Saga K. et al. Accumulation of cytosolic calcium induces necroptotic cell death in human neuroblastoma. Cancer Res 2013;74(4):1056–66. DOI: 10.1158/0008-5472.can-13-1283Galluzzi L., Kepp O., Hett E. et al. Immunogenic cell death in cancer: concept and therapeutic implications. J Transl Med 2023;21(1):162. DOI: 10.1186/s12967-023-04017-6Mussai F., Egan S., Hunter S. et al. Neuroblastoma arginase activity creates an immunosuppressive microenvironment that impairs autologous and engineered immunity. Cancer Res 2015;75(15):3043–53. DOI: 10.1158/0008-5472.can-14-3443Yau T., Cheng P.N., Chan P. et al. Preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and quality of life study of pegylated recombinant human arginase 1 in patients with advanced hepatocellular carcinoma. Invest New Drugs 2015;33(2):496–504. DOI: 10.1007/s10637-014-0200-8Locatelli F., Pagliara D., De Ioris M.A. et al. GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial. Nat Med 2025;31(11):3689–99. DOI: 10.1038/s41591-025-03874-6Li C., Sharma S., Heczey A.A. et al. Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma. Nat Med 2025;31(4):1125–9. DOI: 10.1038/s41591-025-03513-0Bosse K.R., Raman P., Zhu Z. et al. Identification of GPC2 as an oncoprotein and candidate immunotherapeutic target in high-risk neuroblastoma. Cancer Cell 2017;32(3):295–309:e12. DOI: 10.1016/j.ccell.2017.08.003Li N., Fu H., Hewitt S.M. et al. Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma. Proc Natl Acad Sci USA 2017;114(32):E6623–31. DOI: 10.1073/pnas.1706055114Moog-Lutz C., Degoutin J., Gouzi J.Y. et al. Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin. J Biol Chem 2005;280(28):26039–48. DOI: 10.1074/jbc.m501972200Walker A.J., Majzner R.G., Zhang L. et al. Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase. Mol Ther 2017;25(9):2189–201. DOI: 10.1016/j.ymthe.2017.06.008Okada R., Reyes-González J.M., Rodriguez C. et al. GPC2-targeted CAR T cells engineered with NFAT-inducible membrane-tethered IL15/IL21 exhibit enhanced activity against neuroblastoma. Cancer Immunol Res 2025;13(9):1363–73. DOI: 10.1158/2326-6066.cir-24-0975Giudice A.M., Roth S.L., Matlaga S. et al. Reprogramming the neuroblastoma tumor immune microenvironment to enhance GPC2 CAR T cells. Mol Ther 2025;33(9):4552–69. DOI: 10.1016/j.ymthe.2025.05.025Zeromski J., Nyczak E., Dyszkiewicz W. Significance of cell adhesion molecules, CD56/NCAM in particular, in human tumor growth and spreading. Folia Histochem Cytobiol 2001;39(Suppl. 2):36–7.Crossland D.L., Denning W.L., Ang S. et al. Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models. Oncogene 2018;37(27):3686–97. DOI: 10.1038/s41388-018-0187-2Bodden M., Häcker A., Röder J. et al. Co-expression of an IL-15 superagonist facilitates self-enrichment of GD2-targeted CAR-NK cells and mediates potent cell killing in the absence of IL-2. Cancers 2023;15(17):4310. DOI: 10.3390/cancers15174310Moghimi B., Muthugounder S., Jambon S. et al. Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma. Nat Commun 2021;12(1):511. DOI: 10.1038/s41467-020-20785-xSuurs F.V., Hooge M.N.L., De Vries E.G. et al. A review of bispecific antibodies and antibody constructs in oncology and clinical challenges. Pharmacol Ther 2019;201:103–19. DOI: 10.1016/j.pharmthera.2019.04.006Kitidee K., Amonyingcharoen S., Preedagasamzin S. et al. Combining CD3/GD2 bispecific T cell engager with human Vγ9Vδ2 T cells facilitates neuroblastoma cell targeting and killing in vitro. PLoS One 2025;20(6):e0325389. DOI: 10.1371/journal.pone.0325389Muthukutty P., Yoo S.Y. Oncolytic virus engineering and utilizations: cancer immunotherapy perspective. Viruses 2023;15(8):1645. DOI: 10.3390/v15081645Chu Y., Tian M., Saini U. et al. Combinatorial immunotherapy with anti-ROR1 CAR NK cells and an IL-21 secreting oncolytic virus against neuroblastoma. Mol Ther Oncol 2024;33(1):200927. DOI: 10.1016/j.omton.2024.200927Wing A., Fajardo C.A., Posey A.D. et al. Improving CART-cell therapy of solid tumors with oncolytic virus-driven production of a bispecific T-cell engager. Cancer Immunol Res 2018;6(5):605–16. DOI: 10.1158/2326-6066.cir-17-0314Caescu C.I., Guo X., Tesfa L. et al. Colony stimulating factor-1 receptor signaling networks inhibit mouse macrophage inflammatory responses by induction of microRNA-21. Blood 2015;125(8):e1–13. DOI: 10.1182/blood-2014-10-608000Mao Y., Eissler N., Blanc K.L. et al. Targeting suppressive myeloid cells potentiates checkpoint inhibitors to control spontaneous neuroblastoma. Clin Cancer Res 2016;22(15):3849–59. DOI: 10.1158/1078-0432.ccr-15-1912Wu H., Sheard M.A., Malvar J. et al. Anti-CD105 antibody eliminates tumor microenvironment cells and enhances anti-GD2 antibody immunotherapy of neuroblastoma with activated natural killer cells. Clin Cancer Res 2019;25(15):4761–74. DOI: 10.1158/1078-0432.ccr-18-3358Rohila D., Park I.H., Pham T.V. et al. Targeting macrophage Syk enhances responses to immune checkpoint blockade and radiotherapy in high-risk neuroblastoma. Front Immunol 2023;14:1148317. DOI: 10.3389/fimmu.2023.1148317